Kovitz Investment Group Partners
TXG icon

Kovitz Investment Group Partners’s 10x Genomics TXG Stock Holding History

Kovitz Investment Group Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42,623
Closed -$498K – 1256
2025
Q3 		$498K Buy
+42,623
New +$556K ﹤0.01% 1036

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kovitz Investment Group Partners's TXG Position: Q4 2025 in Review

Kovitz Investment Group Partners sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 42,623 shares — an estimated $498K sold.

Kovitz Investment Group Partners first reported a position in TXG in Q3 2025 and held it in 1 quarter. The position peaked at $498K in Q3 2025. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Kovitz Investment Group Partners reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 42,623 10x Genomics shares in Q4 2025, an estimated $498K.
  • Kovitz Investment Group Partners first reported a position in 10x Genomics in Q3 2025 and held it in 1 quarter.
  • Kovitz Investment Group Partners's 10x Genomics position peaked at $498K in Q3 2025.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q4 2025, filed 20 Feb 2026.